Lots of traders, investors, analysts turned heavily positive about 2 years before CLSN's liver cancer drug phase III data and pps surged very high. However bashers said many times that they were not optimistic on Phase I,II data and believe it will fail in Phase III. Yes, bashers were 100% right on CLSN's liver cancer drug and it failed in Phase III early last year. PPS hit penny land overnight, later it did R/S to stay listed on nasdaq. Biotech stocks are of very high risk specially when it a small company with one potential drug candidate under development, no revenue and not enough cash on hand etc etc. I don't know why so much hype here when GALE's lead drug candidate Neuvax is 3+ years away to get a final decision. Pre-clinical (animal model), Phase I, Phase II positive data are not the confirmation of positive result as those are the test results from a small number of living population. Every life is different in its chemistry and genetic functionality and thus Phase III with much larger patient counts, is the true challenge for a drug to overcome. So it's too early to bet on a positive outcome from Neuvax phase III. ( a vision of a business philosopher ).